Implications of the current tuberculosis treatment landscape for future regimen change

International Journal of Tuberculosis and Lung Disease

Volumn 15, Issue 6, 2011, Pages

  Wells, William A ^a   Konduri, N ^b   Chen, C ^a,c   Lee, D ^b   Ignatius, H R ^a   Gardiner, E ^a   Schwalbe, N R ^a,d  

^a GLOBAL ALLIANCE FOR TB DRUG DEVELOPMENT   (United States)

^b MANAGEMENT SCIENCES FOR HEALTH   (United States)

^c RESULTS USA   (United States)

^d Program Delivery Team   (Switzerland)

Author keywords

High burden countries; Regimen change; Tuberculosis drugs

Indexed keywords

ETHAMBUTOL; GATIFLOXACIN; ISONIAZID; MOXIFLOXACIN; PYRAZINAMIDE; QUINOLINE DERIVED ANTIINFECTIVE AGENT; RIFAMPICIN;

ARTICLE; CLINICAL TRIAL; COST BENEFIT ANALYSIS; COST EFFECTIVENESS ANALYSIS; DRUG DOSE REGIMEN; DRUG SENSITIVITY; GEOGRAPHIC DISTRIBUTION; HUMAN; INTERVIEW; LUNG TUBERCULOSIS; MAJOR CLINICAL STUDY; POPULATION RESEARCH; PRACTICE GUIDELINE; PRIORITY JOURNAL; TREATMENT RESPONSE; TUBERCULOSIS CONTROL;

ANTITUBERCULAR AGENTS; DEVELOPING COUNTRIES; DRUG COMBINATIONS; DRUG THERAPY, COMBINATION; HEALTH POLICY; HUMANS; INTERVIEWS AS TOPIC; PRIVATE SECTOR; PUBLIC SECTOR; TUBERCULOSIS;

EID: 79954922927     PISSN: 10273719     EISSN: None     Source Type: Journal    
DOI: 10.5588/ijtld.10.0094     Document Type: Article

References (33)

1. Global Alliance for TB Drug Development. New TB regimens: What countries want. The value proposition of existing and new first-line regimens for drug-susceptible tuberculosis. New York, NY, USA: Global Alliance for TB Drug Development, 2009.
2. Williams H A, Durrheim D, Shretta R. The process of changing national malaria treatment policy: lessons from country-level studies. Health Policy Plan 2004; 19: 356-370. (Pubitemid 39472139)
3. Rieder H L, Arnadottir T, Trebucq A, Enarson D A. Tuberculosis treatment: dangerous regimens? Int J Tuberc Lung Dis 2001; 5: 1-3.
4. Jindani A, Nunn A J, Enarson D A. Two 8-month regimens of chemotherapy for treatment of newly diagnosed pulmonary tuberculosis: international multicentre randomised trial. Lancet 2004; 364: 1244-1251. (Pubitemid 39311345)
5. World Health Organization. Treatment of tuberculosis. Guidelines for national programmes. WHO/CDS/TB/2003.313. Geneva, Switzerland: WHO, 2003.
6. World Health Organization. Treatment of tuberculosis: guidelines for national programmes, 4th ed. WHO/HTM/TB/2009. 420. Geneva, Switzerland: WHO, 2009.
7. Foundation for Innovative New Diagnostics, UNDP/World Bank/WHO Special Programme for Research and Training in Tropical Diseases. Diagnostics for tuberculosis: global demand and market potential. Geneva, Switzerland: FIND/TDR, 2006.
8. Bayer R, Wilkinson D. Directly observed therapy for tuberculosis: history of an idea. Lancet 1995; 345: 1545-1548.
9. Newell J N, Baral S C, Pande S B, Bam D S, Malla P. Family-member DOTS and community DOTS for tuberculosis control in Nepal: cluster-randomised controlled trial. Lancet 2006; 367: 903-909.
10. World Health Organization. Implementing the Stop TB Strategy: a handbook for national tuberculosis control programmes. WHO/HTM/TB/2008.401. Geneva, Switzerland: WHO, 2008.
11. Wells W A, Konduri N, Chen C, et al. TB regimen change in the high burden countries. Int J Tuberc Lung Dis 2010; 14: 1538-1547.
12. Uplekar M. Involving private health care providers in delivery of TB care: global strategy. Tuberculosis 2003; 83: 156-164. (Pubitemid 36683566)
13. Pantoja A, Lönnroth K, Lal S S, et al. Economic evaluation of public-private mix for tuberculosis care and control, India. Part II. Cost and cost-effectiveness. Int J Tuberc Lung Dis 2009; 13: 705-712.
14. Malmborg R, Mann G, Thomson R, Squire S B. Can publicprivate collaboration promote tuberculosis case detection among the poor and vulnerable? Bull World Health Organ 2006; 84: 752-758.
15. Ginsberg A M. Emerging drugs for active tuberculosis. Semin Respir Crit Care Med 2008; 29: 552-559.
16. Stop TB Partnership, World Health Organization. New technologies for tuberculosis control: a framework for adoption, introduction and implementation. WHO/HTM/STB/2007.40. Geneva, Switzerland: WHO, 2007.
17. World Health Organization. WHO report 2009. Global tuberculosis control: epidemiology, strategy, financing. WHO/HTM/TB/2009.411. Geneva, Switzerland: WHO, 2009.
18. Glaziou P. A new perspective on TB disease burden and TB control in Viet Nam: lessons from a prevalence survey. DOTS Expansion Working Group meeting on improved case detection. Geneva, Switzerland: Stop TB Partnership, 2009. http://www.stoptb.org/wg/dots-expansion/assets/documents/CD2009/ Presentations%20Day%202/Prevalence%20survey%20Viet%20Nam%20Dr%20P.Glaziou.ppt Accessed March 2011.
19. World Health Organization. The Global Plan to Stop TB 2006-2015: progress report 2006-2008. WHO/HTM/STB/2009.59. Geneva, Switzerland: WHO, 2009.
20. World Health Organization. Treatment of tuberculosis. Guidelines for national programmes. WHO/TB/97.220. Geneva, Switzerland: WHO, 1997.
21. World Health Organization. Fixed-dose combination tablets for the treatment of tuberculosis. Report of an informal meeting held in Geneva, Tuesday 27 April 1999. Geneva, Switzerland: WHO, 1999.
22. Wells W A, Ge C F, Patel N, et al. Size and usage patterns of private TB drug markets in the high-burden countries. PLoS ONE 2011. [In press]
23. Uplekar M W, Shepard D S. Treatment of tuberculosis by private general practitioners in India. Tubercle 1991; 72: 284-290.
24. Lonnroth K, Uplekar M, Blanc L. Hard gains through soft contracts: productive engagement of private providers in tuberculosis control. Bull World Health Organ 2006; 84: 876-883. (Pubitemid 44714423)
25. Hopewell P C, Pai M, Maher D, Uplekar M, Raviglione M C. International standards for tuberculosis care. Lancet Infect Dis 2006; 6: 710-725. (Pubitemid 44740086)
26. Salomon J A, Lloyd-Smith J O, Getz W M, et al. Prospects for advancing tuberculosis control efforts through novel therapies. PLoS Med 2006; 3: e273.
27. Abu-Raddad L J, Sabatelli L, Achterberg J T, et al. Epidemiological benefits of more-effective tuberculosis vaccines, drugs, and diagnostics. Proc Natl Acad Sci USA 2009; 106: 13980-13985.
28. Enarson D, Rieder H, Arnadottir T, Trébucq A. Management of tuberculosis. A guide for low income countries. 5th ed. Paris, France: International Union Against Tuberculosis and Lung Disease, 2000.
29. World Health Organization. Interim recommendations for the surveillance of drug resistance in tuberculosis. WHO/HTM/TB/2007.385. Geneva, Switzerland: WHO, 2007.
30. Tuberculosis bacteriology - priorities and indications in high prevalence countries: position of the technical staff of the Tuberculosis Division of the International Union Against Tuberculosis and Lung Disease. Int J Tuberc Lung Dis 2005; 9: 355-361.
31. Van Deun A, Salim A H, Rigouts L, Rahman M, Fissette K, Portaels F. Evaluation of tuberculosis control by periodic or routine susceptibility testing in previously treated cases. Int J Tuberc Lung Dis 2001; 5: 329-338. (Pubitemid 32397583)
32. Barber S L, Smid M, Hennig C, Huang B, Arifaj D. Multidrug-resistant tuberculosis and quality-assured medicines. Lancet 2009; 374: 292.
33. Stop TB Partnership, World Health Organization. Global plan to stop TB 2006-2015. WHO/HTM/STB/2006.35. Geneva, Switzerland: WHO, 2006.